NeoGenomics offers lab services for oncology clinical trials
For current Clarient clients only, access your Clarient resources here.
Tuesday, July 26th, 2016
SP142 for bladder cancer now available
Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.
Comprehensive detection of sarcoma transocations
by next-gen sequencing to enhance diagnosis,
subclassification, and treatment
Sarcoma Fusion Profile
Targeted next-gen sequencing panel that detects
significant translocations in the genes NTRK1,
NTRK3, and RET
NGS Thyroid Fusion Profile